Alizé Pharma begins Phase II trial of AZP-531 to treat Prader-Willi syndrome
The randomized, double blind and placebo controlled trial, which will be conducted in several European countries, is designed to assess the safety and effects of a two-week treatment
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.